Chong Kin Liam
Overview
Explore the profile of Chong Kin Liam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poh M, Balakrishnan S, Tan S, Abidin M, Liam C, Tan J, et al.
Transl Lung Cancer Res
. 2024 Aug;
13(7):1649-1659.
PMID: 39118879
Background: Response rates of epidermal growth factor receptor ()-mutated advanced non-small cell lung cancer (NSCLC) to lower doses of osimertinib [20 mg once daily (OD) and 40 mg OD] are...
2.
Wu Y, Guarneri V, Voon P, Lim B, Yang J, Wislez M, et al.
Lancet Oncol
. 2024 Aug;
25(8):989-1002.
PMID: 39089305
Background: Patients with EGFR-mutated non-small-cell lung cancer (NSCLC) and MET amplification as a mechanism of resistance to first-line osimertinib have few treatment options. Here, we report the primary analysis of...
3.
Poh M, Chai C, Liam C, Ho G, Pang Y, Hasbullah H, et al.
Transl Lung Cancer Res
. 2024 Mar;
13(2):307-320.
PMID: 38496703
Background: Afatinib can be started at a dose lower than the recommended starting dose of 40 mg/day for the treatment of epidermal growth factor receptor ()-mutant non-small cell lung cancer...
4.
Loong S, Liam C, Karunakaran R, Tan K, Mahfodz N, AbuBakar S
J Int Med Res
. 2024 Jan;
52(1):3000605231214464.
PMID: 38216150
An increasing number of reports have described the pathogenic nature of several non-classical spp. Among them, and have been implicated in a myriad of respiratory-associated infections in humans and animals....
5.
Kee Y, Wong C, Abdul Aziz M, Zakaria M, Mohd Shaarif F, Ng K, et al.
Int J Chron Obstruct Pulmon Dis
. 2023 Nov;
18:2623-2631.
PMID: 38022826
Purpose: Readmission of chronic obstructive pulmonary disease (COPD) has been used as a measure of performance for COPD care. This study aimed to determine the rate of readmission of COPD...
6.
Liam C, Yew C, Pang Y, Wong C, Poh M, Tan J, et al.
BMC Cancer
. 2023 Jul;
23(1):659.
PMID: 37452277
Background: In non-small cell lung cancer (NSCLC), there may be a relationship between programmed death-ligand 1 (PD-L1) expression, driver mutations and cigarette smoking. Methods: In this single-center retrospective study, the...
7.
Soo C, Ong D, Chin K, Sia L, Munusamy V, Ibrahim N, et al.
Respirol Case Rep
. 2023 Jun;
11(7):e01181.
PMID: 37350988
Neoadjuvant chemotherapy is a therapeutic option for potentially resectable non-small cell lung cancer (NSCLC). The role of neoadjuvant targeted therapy (NTT) remains less explored. This case highlights the use of...
8.
Liam C, Ahmad A, Hsia T, Zhou J, Kim D, Soo R, et al.
Clin Cancer Res
. 2023 Mar;
29(10):1879-1886.
PMID: 36971777
Purpose: The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patients with MET-altered EGFR-mutant NSCLC (data cut-off: September 3,...
9.
Ahn M, Mendoza M, Pavlakis N, Kato T, Soo R, Kim D, et al.
Clin Lung Cancer
. 2022 Sep;
23(8):670-685.
PMID: 36151006
Non-small cell lung cancer (NSCLC) is a heterogeneous disease, with many oncogenic driver mutations, including de novo mutations in the Mesenchymal Epithelial Transition (MET) gene (specifically in Exon 14 [ex14]),...
10.
Loh T, Pang Y, Liam C, Chew M, Tan J
Respirol Case Rep
. 2022 Sep;
10(10):e01030.
PMID: 36090023
Metastatic pulmonary calcification (MPC) is characterized by deposition of calcium in the normal lung parenchyma secondary to elevation of serum calcium. Most patients are asymptomatic and routine chest radiograph is...